Literature DB >> 27030327

[Clinical manifestations of asthma during combination therapy using ceruloplasmin].

V M Provotorov1, A V Budnevsky1, Yu I Filatova1.   

Abstract

AIM: To estimate the time course of clinical changes in patients with asthma during combination therapy using ceruloplasmin (CP).
MATERIALS AND METHODS: A total of 92 asthmatic patients were examined. Their medical history data were collected; external lung function testing and clinical, laboratory, and instrumental examinations, involving the determination of the indicators of lipid peroxidation (LPO) (malonic dialdehyde (MDA), methemoglobin, carboxyhemoglobin) and the antioxidant system (superoxide dismutase (COD), sulfhydryl groups), were performed in all the patients over time. According to the therapy used, the patients were divided into 2 groups matched for gender, age, and clinical manifestations of the disease. A study group consisted of 45 patients who took CP in addition to conventional therapy. A comparison group included 47 patients receiving standard therapy.
RESULTS: During the combination therapy using CP, the asthmatic patients showed a reduction in the elevated concentrations of MDA, methemoglobin, and carboxyhemoglobin and increases in the activity of COD and in the levels of sulfhydryl groups, which was followed by a considerable clinical improvement. During the conventional therapy, the indicators of LPO remained high and those of the antioxidant system did low, suggesting permanent oxidative stress.
CONCLUSION: CP incorporation into the combination therapy of asthmatic patients contributes to elimination of prooxidant-antioxidant imbalance, which is followed by a marked positive clinical effect.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27030327     DOI: 10.17116/terarkh201688336-39

Source DB:  PubMed          Journal:  Ter Arkh        ISSN: 0040-3660            Impact factor:   0.467


  2 in total

1.  Clinical efficacy of recombinant human latrophilin 3 antibody in the treatment of pediatric asthma.

Authors:  Maohua Liu; Jingxiu Zhang; Chengjun Liu
Journal:  Exp Ther Med       Date:  2017-10-25       Impact factor: 2.447

2.  Serum Ceruloplasmin as a Potential Clinical Biomarker in Atopic Dermatitis.

Authors:  Youin Bae; Seong-Jin Kim
Journal:  Ann Dermatol       Date:  2022-08       Impact factor: 0.722

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.